Current Rheumatology Reports

, Volume 14, Issue 1, pp 71–78 | Cite as

Drug-Induced Lupus Anticoagulants and Antiphospholipid Antibodies

ANTIPHOSPHOLIPID SYNDROME (RAS ROUBEY, SECTION EDITOR)

Abstract

Lupus anticoagulants (LA) are immunoglobulins (IgG, IgM, and/or IgA) which interfere with one or more of phospholipid-dependent in vitro coagulation tests, eg, activated partial thromboplastin time (aPTT), kaolin clotting time (KCT), dilute Russell viper venom time (dRVVT), and dilute prothrombin time (dPT). LAs may be seen in a variety of clinical settings including the primary antiphospholipid syndrome (APS), systemic lupus erythematosus (SLE), other autoimmune diseases, secondary to infections, malignancies, and in association with certain drugs. LAs associated with the antiphospholipid syndrome and other autoimmune disease recognize certain phospholipid-binding proteins (β2-glycoprotein I [β2GPI] or prothrombin). Many drugs have been implicated as possibly causing LAs, although the majority of such cases are limited to a select few. Drug-induced LAs are heterogeneous, differing in laboratory findings as well as related clinical complications. This paper reviews the English medical literature on drug-induced LA and potential mechanisms of induction.

Keywords

Lupus anticoagulants Drug-induced Thrombosis Circulating inhibitors Antiphospholipid syndrome 

Notes

Disclosure

No potential conflicts of interest relevant to this article were reported.

References

  1. 1.
    Conley CL, Hartmann RC. A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Clin Invest. 1952;31:621–2.Google Scholar
  2. 2.
    Shapiro SS. The lupus anticoagulant/antiphospholipid syndrome. Annu Rev Med. 1996;47:533–53.PubMedCrossRefGoogle Scholar
  3. 3.
    Lechner K. Acquired inhibitors in nonhemophilic patients. Haemostasis. 1974;3:65–93.PubMedGoogle Scholar
  4. 4.
    Bowie EJW, Thompson Jr JH, Pascuzzi CA, Owen Jr CA. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Lab Clin Med. 1963;62:416–30.PubMedGoogle Scholar
  5. 5.
    Feinstein DI, Rapaport SI. Acquired inhibitors of blood coagulation. Prog Hemostas Thromb. 1972;1:75–95.Google Scholar
  6. 6.
    Schroeder HA, Morrow JD, Perry Jr HM. Studies on the control of hypertension by hyphex. I. Effects on blood pressure. Circulation. 1953;8(5):672–80.PubMedGoogle Scholar
  7. 7.
    Lindqvist TT. Lupus erythematosus disseminatus after administration of mesantoin; report of two cases. Acta Med Scand. 1957;158(2):131–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Ladd AT. Procainamide-induced lupus erythematosus. N Engl J Med. 1962;267:1357–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Borchers AT, Keen CL, Gershwin ME. Drug-induced lupus. Ann N Y Acad Sci. 2007;1108:166–82.PubMedCrossRefGoogle Scholar
  10. 10.
    Schleider MA, Nachman RL, Jaffe EA, Coleman M. A clinical study of the lupus anticoagulant. Blood. 1976;48(4):499–509.PubMedGoogle Scholar
  11. 11.
    Bell WR, Boss GR, Wolfson JS. Circulating anticoagulant in the procainamide-induced lupus syndrome. Arch Intern Med. 1977;137(10):1471–3.PubMedCrossRefGoogle Scholar
  12. 12.
    Davis S, Furie BC, Griffin JH, Furie B, Willey R. Circulating inhibitors of blood coagulation associated with procainamide-induced lupus erythematosus. Am J Hematol. 1978;4(4):401–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Galanakis DK, Newman J, Summers D. Circulating thrombin time anticoagulant in a procainamide-induced syndrome. JAMA. 1978;239(18):1873–4.PubMedCrossRefGoogle Scholar
  14. 14.
    Mueh JR, Herbst KD, Rapaport SI. Thrombosis in patients with the lupus anticoagulant. Ann Intern Med. 1980;92:156–9.PubMedGoogle Scholar
  15. 15.
    Edwards RL, Rick ME, Wakem CJ. Studies on a circulating anticoagulant in procainamide-induced lupus erythematosus. Arch Intern Med. 1981;141(12):1688–90.PubMedCrossRefGoogle Scholar
  16. 16.
    Sanfelippo MJ, Drayna CJ. Prekallikrein inhibition associated with the lupus anticoagulant: a mechanism of thrombosis. Am J Clin Pathol. 1982;77:275–9.PubMedGoogle Scholar
  17. 17.
    O’Brien DC, Shimomura SK. Procainamide and the lupus anticoagulant. Drug Intell Clin Pharm. 1984;18:971.Google Scholar
  18. 18.
    Gastineau DA, Kazmier FJ, Nichols WL, Bowie EJ. Lupus anticoagulant: an analysis of the clinical and laboratory features of 219 cases. Am J Hematol. 1985;19:265–75.PubMedCrossRefGoogle Scholar
  19. 19.
    Day HJ, Cherrey R, O'Hara D, Carebello J. Incidence of procainamide-induced anticoagulant. Thromb Haemost. 1987;58:394. Ref Type: Abstract.Google Scholar
  20. 20.
    Weber MT, Hocking WG. Procainamide induced lupus anticoagulant. Wis Med J. 1988;87(9):30–2.PubMedGoogle Scholar
  21. 21.
    Heyman MR, Flores RH, Edelman BB, Carliner NH. Procainamide-induced lupus anticoagulant. South Med J. 1988;81(7):934–6.PubMedCrossRefGoogle Scholar
  22. 22.
    Li GC, Greenberg CS, Currie MS. Procainamide-induced lupus anticoagulants and thrombosis. South Med J. 1988;81(2):262–4.PubMedCrossRefGoogle Scholar
  23. 23.
    Schlesinger PA, Peterson LA. Procainamide-associated lupus anticoagulants and thrombotic events. Arthritis Rheum. 1988;31:S54. Ref Type: Abstract.Google Scholar
  24. 24.
    Asherson RA, Zulman J, Hughes GR. Pulmonary thromboembolism associated with procainamide induced lupus syndrome and anticardiolipin antibodies. Ann Rheum Dis. 1989;48:232–5.PubMedCrossRefGoogle Scholar
  25. 25.
    Kushner M, Simonian N. Lupus anticoagulants, anticardiolipin antibodies, and cerebral ischemia. Stroke. 1989;20:225–9.PubMedCrossRefGoogle Scholar
  26. 26.
    List AF, Doll DC. Thrombosis associated with procainamide-induced lupus anticoagulant. Acta Haematol. 1989;82(1):50–2.PubMedCrossRefGoogle Scholar
  27. 27.
    Humphries JE. Persistent procainamide-associated lupus anticoagulant. Clin Hemost Rev. 1996;10:13.Google Scholar
  28. 28.
    Merrill JT, Shen C, Gugnani M, Lahita RG, Mongey AB. High prevalence of antiphospholipid antibodies in patients taking procainamide. J Rheumatol. 1997;24(6):1083–8.PubMedGoogle Scholar
  29. 29.
    Freeman NJ, Fajardo L, Carvalho A. Simultaneous procainamide-induced immune thrombocytopenia and lupus anticoagulant. Am J Hematol. 1995;48(2):133–4.PubMedGoogle Scholar
  30. 30.
    Kameda H, Mimori T, Kaburaki J, Fujii T, Takahashi T, Akaishi M, et al. Systemic sclerosis complicated by procainamide-induced lupus and antiphospholipid syndrome. Br J Rheumatol. 1998;37(11):1236–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Triplett DA, Brandt JT, Musgrave KA, Orr CA. The relationship between lupus anticoagulants and antibodies to phospholipid. JAMA. 1988;259:550–4.PubMedCrossRefGoogle Scholar
  32. 32.
    Walker TS, Triplett DA, Javed N, Musgrave K. Evaluation of lupus anticoagulants: antiphospholipid antibodies, endothelium associated immunoglobulin, endothelial prostacyclin secretion, and antigenic protein S levels. Thromb Res. 1988;51:267–81.PubMedCrossRefGoogle Scholar
  33. 33.
    Clyne LP, Farber LR, Chopyk RL. Procainamide-induced circulating anticoagulants in a congenitally-deficient factor XI patient. Folia Haematol Int Mag Klin Morphol Blutforsch. 1989;116(2):239–44.PubMedGoogle Scholar
  34. 34.
    Triplett DA, Brandt JT, Kaczor D, Schaeffer J. Laboratory diagnosis of lupus inhibitors: a comparison of the tissue thromboplastin inhibition procedure with a new platelet neutralization procedure. Am J Clin Pathol. 1983;79(6):678–82.PubMedGoogle Scholar
  35. 35.
    Blomgren SE, Condemi JJ, Bignall MC, Vaughan JH. Antinuclear antibody induced by procainamide. A prospective study. N Engl J Med. 1969;281(2):64–6.PubMedCrossRefGoogle Scholar
  36. 36.
    Bird MR, O’Neill AI, Buchanan RR, Ibrahim KM, Des PJ. Lupus anticoagulant in the elderly may be associated with both quinine and quinidine usage. Pathology. 1995;27(2):136–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Lavie CJ, Biundo J, Quinet RJ, Waxman J. Systemic lupus erythematosus (SLE) induced by quinidine. Arch Intern Med. 1985;145(3):446–8.PubMedCrossRefGoogle Scholar
  38. 38.
    Jeffrey RF. Transient lupus anticoagulant and fansidar therapy. Postgrad Med J. 1986;62:893–4.PubMedCrossRefGoogle Scholar
  39. 39.
    Canoso RT, Hutton RA, Deykin D. A chlorpromazine-induced inhibitor of blood coagulation. Am J Hematol. 1977;2(2):183–91.PubMedCrossRefGoogle Scholar
  40. 40.
    Zucker S, Zarrabi MH, Romano GS, Miller F. IgM inhibitors of the contact activation phase of coagulation in chlorpromazine-treated patients. Br J Haematol. 1978;40(3):447–57.PubMedCrossRefGoogle Scholar
  41. 41.
    Zarrabi MH, Zucker S, Miller F, Derman RM, Romano GS, Hartnett JA, et al. Immunologic and coagulation disorders in chlorpromazine-treated patients. Ann Intern Med. 1979;91(2):194–9.PubMedGoogle Scholar
  42. 42.
    Canoso RT, Sise HS. Chlorpromazine-induced lupus anticoagulant and associated immunologic abnormalities. Am J Hematol. 1982;13(2):121–9.PubMedCrossRefGoogle Scholar
  43. 43.
    Tollefson G, Rodysill K, Cusulos M. A circulating lupus-like coagulation inhibitor induced by chlorpromazine. J Clin Psychopharmacol. 1984;4(1):49–51.PubMedCrossRefGoogle Scholar
  44. 44.
    Pavlidakey GP, Hashimoto K, Heller GL, Daneshvar S. Chlorpromazine-induced lupuslike disease. Case report and review of the literature. J Am Acad Dermatol. 1985;13(1):109–15.PubMedCrossRefGoogle Scholar
  45. 45.
    Zengotita HE, Holt RJ. Neuroleptic drug-induced coagulopathy: mechanism of reaction and duration of effect. J Clin Psychiatry. 1986;47(1):35–7.PubMedGoogle Scholar
  46. 46.
    Canoso RT, De Oliveira RM. Chlorpromazine-induced anticardiolipin antibodies and lupus anticoagulant: absence of thrombosis. Am J Hematol. 1988;27:272–5.PubMedCrossRefGoogle Scholar
  47. 47.
    Steen VD, Ramsey-Goldman R. Phenothiazine-induced systemic lupus erythematosus with superior vena cava syndrome: case report and review of the literature. Arthritis Rheum. 1988;31(7):923–6.PubMedCrossRefGoogle Scholar
  48. 48.
    el-Mallakh RS, Donaldson JO, Kranzler HR, Racy A. Phenothiazine-associated lupus anticoagulant and thrombotic disease. Psychosomatics. 1988;29(1):109–13.PubMedCrossRefGoogle Scholar
  49. 49.
    Jude B, Goudemand J, Dolle I, Caron C, Watel A, Tiry C, et al. Lupus anticoagulant: a clinical and laboratory study of 100 cases. Clin Lab Haematol. 1988;10:41–51.PubMedGoogle Scholar
  50. 50.
    Lillicrap DP, Pinto M, Benford K, Ford PM, Ford S. Heterogeneity of laboratory test results for antiphospholipid antibodies in patients treated with chlorpromazine and other phenothiazines. Am J Clin Pathol. 1990;93:771–5.PubMedGoogle Scholar
  51. 51.
    Kaslow KA, Rosse RB, Zeller JA, Nagy MS, Deustch SI. Phenothiazine-induced lupus anticoagulant. J Clin Psychiatry. 1992;53(3):103–4.PubMedGoogle Scholar
  52. 52.
    Morgan M, Chesterman CN, Downs K, Biggs JC. Clinical analysis of 125 patients with the lupus anticoagulant. Aust N Z J Med. 1993;23:151–6.PubMedCrossRefGoogle Scholar
  53. 53.
    Gharavi AE, Sammaritano LR, Wen J, Miyawaki N, Morse JH, Zarrabi MH, et al. Characteristics of human immunodeficiency virus and chlorpromazine induced antiphospholipid antibodies: Effect of β2-glycoprotein I on binding to phospholipid. J Rheumatol. 1994;21:94–9.PubMedGoogle Scholar
  54. 54.
    Tribout B, Gosset O, Fuentes V, Gross S, Fardelonne P, Lernout P, et al. High prevalence of antiphospholipid antibodies without increased risk of thrombosis in psychiatric patients treated chronically with neuroleptic drugs. Nouv Rev Fr Hematol. 1995;37:S79–82.Google Scholar
  55. 55.
    Matsukawa Y, Satoh M, Itoh T, Nishinarita S, Horie T, Abe K, et al. Plasmapheresis for a schizophrenic patient with drug-induced lupus anti-coagulant. J Int Med Res. 1996;24(1):147–50.PubMedGoogle Scholar
  56. 56.
    Goldman LS, Hudson JI, Weddington Jr WW. Lupus-like illness associated with chlorpromazine. Am J Psychiatry. 1980;137(12):1613–4.PubMedGoogle Scholar
  57. 57.
    Dubois EL, Tallman E, Wonka RA. Chlorpromazine-induced systemic lupus erythematosus: case report and review of the literature. JAMA. 1972;221(6):595–6.PubMedCrossRefGoogle Scholar
  58. 58.
    Berglund S, Gottfries CG, Gottfries I, Stormby K. Chlorpromazine-induced antinuclear factors. Acta Med Scand. 1970;187(1–2):67–74.PubMedGoogle Scholar
  59. 59.
    Canoso RT, Romero JA, Yunis EJ. Immunogenetic markers in chlorpromazine-induced tardive dyskinesia. J Neuroimmunol. 1986;12(3):247–52.PubMedCrossRefGoogle Scholar
  60. 60.
    Kahn G, Davis BP. In vitro studies on longwave ultraviolet light-dependent reactions of the skin photosensitizer chlorpromazine with nucleic acids, purines and pyrimidines. J Invest Dermatol. 1970;55(1):47–52.PubMedCrossRefGoogle Scholar
  61. 61.
    Kanjolia A, Valigorsky JM, Joson-Pasion ML. Clozaril-induced lupus anticoagulant. Am J Hematol. 1997;54(4):345–6.PubMedCrossRefGoogle Scholar
  62. 62.
    Alarcon-Segovia D, Fishbein E, Reyes PA, Dies H, Shwadsky S. Antinuclear antibodies in patients on anticonvulsant therapy. Clin Exp Immunol. 1972;12(1):39–47.PubMedGoogle Scholar
  63. 63.
    Beernink DH, Miller III JJ. Anticonvulsant-induced antinuclear antibodies and lupus-like disease in children. J Pediatr. 1973;82(1):113–7.PubMedCrossRefGoogle Scholar
  64. 64.
    Singsen BH, Fishman L, Hanson V. Antinuclear antibodies and lupus-like syndromes in children receiving anticonvulsants. Pediatrics. 1976;57(4):529–34.PubMedGoogle Scholar
  65. 65.
    Drory VE, Korczyn AD. Hypersensitivity vasculitis and systemic lupus erythematosus induced by anticonvulsants. Clin Neuropharmacol. 1993;16(1):19–29.PubMedCrossRefGoogle Scholar
  66. 66.
    Harrison RL, Alperin JB, Kumar D. Concurrent lupus anticoagulants and prothrombin deficiency due to phenytoin use. Arch Pathol Lab Med. 1987;111:719–22.PubMedGoogle Scholar
  67. 67.
    Becker JC, Winkler B, Klingert S, Brocker EB. Antiphospholipid syndrome associated with immunotherapy for patients with melanoma. Cancer. 1994;73(6):1621–4.PubMedCrossRefGoogle Scholar
  68. 68.
    Stricker RB, Barlogie B, Kiprov DD. Acquired factor VIII inhibitor associated with chronic interferon-alpha therapy. J Rheumatol. 1994;21(2):350–2.PubMedGoogle Scholar
  69. 69.
    Ferraccioli G, Mecchia F, Di PE, Fabris M. Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections. Ann Rheum Dis. 2002;61(4):358–61.PubMedCrossRefGoogle Scholar
  70. 70.
    Ferraro-Peyret C, Coury F, Tebib JG, Bienvenu J, Fabien N. Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Arthritis Res Ther. 2004;6(6):R535–43.PubMedCrossRefGoogle Scholar
  71. 71.
    Visvanathan S, Wagner C, Smolen J, St Clair EW, Hegedus R, Baker D, et al. IgG and IgM anticardiolipin antibodies following treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. Arthritis Rheum. 2006;54(9):2840–4.PubMedCrossRefGoogle Scholar
  72. 72.
    Wetter DA, Davis MD. Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clin Proc. 2009;84(11):979–84.PubMedCrossRefGoogle Scholar
  73. 73.
    Makol A, Grover M, Guggenheim C, Hassouna H. Etanercept and venous thromboembolism: a case series. J Med Case Reports. 2010;4:12.PubMedCrossRefGoogle Scholar
  74. 74.
    Nosbaum A, Goujon C, Fleury B, Guillot I, Nicolas JF, Berard F. Arterial thrombosis with anti-phospholipid antibodies induced by infliximab. Eur J Dermatol. 2007;17(6):546–7.PubMedGoogle Scholar
  75. 75.
    Vereckei E, Krivan G, Reti M, Szodoray P, Poor G, Kiss E. Anti-TNF-alpha-induced anti-phospholipid syndrome manifested as necrotizing vasculitis. Scand J Rheumatol. 2010;39(2):175–7.PubMedCrossRefGoogle Scholar
  76. 76.
    Ramos-Casals M, Brito-Zeron P, Soto MJ, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol. 2008;22(5):847–61.PubMedCrossRefGoogle Scholar
  77. 77.
    Merkel PA, Lo GH, Holbrook JT, Tibbs AK, Allen NB, Davis Jr JC, et al. Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener’s Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med. 2005;142(8):620–6.PubMedGoogle Scholar
  78. 78.
    Sebastian JK, Voetsch B, Stone JH, Romay-Penabad Z, Lo GH, Allen NB, et al. The frequency of anticardiolipin antibodies and genetic mutations associated with hypercoagulability among patients with Wegener’s granulomatosis with and without history of a thrombotic event. J Rheumatol. 2007;34(12):2446–50.PubMedGoogle Scholar
  79. 79.
    Davies R, Galloway JB, Watson KD, Lunt M, Symmons DP, Hyrich KL. Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2011;70(10):1831–4.PubMedCrossRefGoogle Scholar
  80. 80.
    Boxer M, Ellman L, Carvalho A. The lupus anticoagulant. Arthritis Rheum. 1976;19(6):1244–8.PubMedCrossRefGoogle Scholar
  81. 81.
    Yokogawa N, Vivino FB. Hydralazine-induced autoimmune disease: comparison to idiopathic lupus and ANCA-positive vasculitis. Mod Rheumatol. 2009;19(3):338–47.PubMedCrossRefGoogle Scholar
  82. 82.
    Orris DJ, Lewis JH, Spero JA, Hasiba U. Blocking coagulation inhibitors in children taking penicillin. J Pediatr. 1980;97(3):426–9.PubMedCrossRefGoogle Scholar
  83. 83.
    Brodeur GM, O’Neill PJ, Willimas JA. Acquired inhibitors of coagulation in nonhemophiliac children. J Pediatr. 1980;96(3 Pt 1):439–41.PubMedGoogle Scholar
  84. 84.
    Vyse T, So AK. Sulphasalazine induced autoimmune syndrome. Br J Rheumatol. 1992;31(2):115–6.PubMedCrossRefGoogle Scholar
  85. 85.
    Alarcon-Segovia D. Drug-induced lupus syndromes. Mayo Clin Proc. 1969;44(9):664–81.PubMedGoogle Scholar
  86. 86.
    Sheng Y, Kandiah DA, Krilis SA. Anti-b2-glycoprotein I autoantibodies from patients with the “antiphospholipid” syndrome bind to b2-glycoprotein I with low affinity: dimerization of b2-glycoprotein I induces a significant increase in anti-b2-glycoprotein I antibody affinity. J Immunol. 1998;161(4):2038–43.PubMedGoogle Scholar
  87. 87.
    McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: b2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA. 1990;87:4120–4.PubMedCrossRefGoogle Scholar
  88. 88.
    Uchman B, Triplett DA. Inhibitor effect of polymyxin B on the X-ase and prothrombinase complex formation. Thromb Haemost. 1989;62:375. Ref Type: Abstract.Google Scholar
  89. 89.
    Brandt JT, Barna LK, Triplett DA. Laboratory identification of lupus anticoagulants: results of the Second International Workshop for Identification of Lupus Anticoagulants. On behalf of the Subcommittee on Lupus Anticoagulants/Antiphospholipid Antibodies of the ISTH. Thromb Haemost. 1995;74(6):1597–603.PubMedGoogle Scholar
  90. 90.
    Cajal Y, Ghanta J, Easwaran K, Surolia A, Jain MK. Specificity for the exchange of phospholipids through polymyxin B mediated intermembrane molecular contacts. Biochemistry. 1996;35(18):5684–95.PubMedCrossRefGoogle Scholar
  91. 91.
    Packman CH, Leddy JP. Drug-related immune hemolytic anemia. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, editors. Williams Hematology. New York: McGraw-Hill; 1995. p. 691–7.Google Scholar
  92. 92.
    Kornberg A, Silber L, Yona R, Kaufman S. Clinical manifestations and laboratory findings in patients with lupus anticoagulants. Eur J Haematol. 1989;42:90–5.PubMedCrossRefGoogle Scholar
  93. 93.
    Sanmarco M, Soler C, Christides C, Raoult D, Weiller PJ, Gerolami V, et al. Prevalence and clinical significance of IgG isotype anti-beta-2-glycoprotein I antibodies in antiphospholipid syndrome: a comparative study with anticardiolipin antibodies. J Lab Clin Med. 1997;129(5):499–506.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Quest Diagnostics Nichols InstituteChantillyUSA
  2. 2.Thurston Arthritis Research Center and Department of Medicine, School of MedicineUniversity of North Carolina at Chapel HillChapel HillUSA

Personalised recommendations